MAGEA3 is an antigen that has been tested in cancer vaccines, although it failed to demonstrate improved progression-free survival in randomized non-small cell lung carcinoma clinical trials [31]. The gene discussed is MAGEA3; the disease is non-small cell lung carcinoma.